Applied Therapeutics Future Growth
Future criteria checks 2/6
Applied Therapeutics is forecast to grow earnings and revenue by 79.6% and 51.7% per annum respectively. EPS is expected to grow by 80.6% per annum. Return on equity is forecast to be -39.1% in 3 years.
Key information
79.6%
Earnings growth rate
80.6%
EPS growth rate
Biotechs earnings growth | 30.4% |
Revenue growth rate | 51.7% |
Future return on equity | -39.1% |
Analyst coverage | Low |
Last updated | 20 May 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 131 | 34 | 73 | 73 | 3 |
12/31/2025 | 46 | -46 | -39 | -39 | 4 |
12/31/2024 | 5 | -163 | -81 | -81 | 4 |
3/31/2024 | 0 | -194 | -67 | -67 | N/A |
12/31/2023 | 10 | -120 | -55 | -55 | N/A |
9/30/2023 | 11 | -97 | -54 | -54 | N/A |
6/30/2023 | 11 | -73 | -59 | -59 | N/A |
3/31/2023 | 11 | -70 | -61 | -61 | N/A |
12/31/2022 | N/A | -83 | -78 | -78 | N/A |
9/30/2022 | N/A | -95 | -89 | -89 | N/A |
6/30/2022 | N/A | -105 | -85 | -85 | N/A |
3/31/2022 | N/A | -105 | -93 | -93 | N/A |
12/31/2021 | N/A | -106 | -91 | -91 | N/A |
9/30/2021 | N/A | -102 | -87 | -87 | N/A |
6/30/2021 | N/A | -104 | -92 | -92 | N/A |
3/31/2021 | N/A | -106 | -82 | -82 | N/A |
12/31/2020 | N/A | -94 | -78 | -78 | N/A |
9/30/2020 | N/A | -88 | -68 | -68 | N/A |
6/30/2020 | N/A | -69 | -55 | -55 | N/A |
3/31/2020 | N/A | -49 | -48 | -48 | N/A |
12/31/2019 | N/A | -46 | -36 | -36 | N/A |
9/30/2019 | N/A | -35 | -30 | -30 | N/A |
6/30/2019 | N/A | -28 | -24 | -24 | N/A |
3/31/2019 | N/A | -23 | -17 | -17 | N/A |
12/31/2018 | N/A | -17 | -11 | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2UV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2UV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2UV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2UV's revenue (51.7% per year) is forecast to grow faster than the German market (5.1% per year).
High Growth Revenue: 2UV's revenue (51.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2UV is forecast to be unprofitable in 3 years.